ANI Pharmaceuticals (ANIP) Set to Post Quarterly Earnings on Thursday

Key Points

• ANI Pharmaceuticals is expected to report Q3 2026 results before Thursday’s market open. Analysts forecast earnings of $2.18 per share on $280.26 million in revenue; the earnings call is scheduled for 8:00 a.m. ET.
• The company exceeded expectations in its previous quarter, reporting $2.21 EPS versus the $2.04 consensus and $266.04 million in revenue. Revenue increased 25.8% year over year.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $99.60 average price target, while ANIP recently traded near $71.71—close to its 52-week low of $69.58.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $2.18 per share and revenue of $280.26 million for the quarter. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Interested persons may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm's revenue was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.80 EPS. On average, analysts expect ANI Pharmaceuticals to post $7.76 EPS for the current fiscal year and $8.32 EPS for the next fiscal year.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $71.71 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The company has a fifty day moving average of $73.16 and a two-hundred day moving average of $77.75. The stock has a market capitalization of $1.65 billion, a PE ratio of 15.45, a P/E/G ratio of 2.34 and a beta of 0.50. ANI Pharmaceuticals has a fifty-two week low of $69.58 and a fifty-two week high of $95.57.

Analyst Ratings Changes

ANIP has been the subject of several research analyst reports. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Wall Street Zen cut ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Guggenheim lowered their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Oppenheimer assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 price objective for the company. Finally, Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an "outperform" rating and a $104.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $99.60.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, Director Jeanne Thoma sold 1,000 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $71.53, for a total value of $71,530.00. Following the completion of the sale, the director directly owned 26,762 shares in the company, valued at $1,914,285.86. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $71.89, for a total transaction of $388,206.00. Following the completion of the sale, the chief executive officer owned 333,689 shares of the company's stock, valued at $23,988,902.21. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 27,562 shares of company stock valued at $2,013,290. 8.10% of the stock is owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI's portfolio includes branded products and generic medicines, as well as treatments for rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.